An interventional study of Programme to Support Breastfeeding in Prematurity; Extreme and Prematurity, sponsored by University of Barcelona. Completed at 2 sites in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-22.
Sponsored by University of Barcelona · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies in Premature Birth with a site in Spain — 16 open to participants now, 17 under way, none of them phase 3. Premature Birth · Spain.
Among the 73 studies in Premature Birth with a site in Spain, this one is the 23rd largest by enrollment of the 56 interventional ones that give a count, is one of 8 that started in 2021, is one of 33 with no phase, and was the 65th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →16 of the 73 studies in Premature Birth with a site in Spain are open now. Recruiting first, the newest first:
Instituto de Investigacion Sanitaria La Fe · Sites in Spain
Ages 0 days–14 days
Maimónides Biomedical Research Institute of Córdoba · Sites in Spain
Ages 0 days–120 days · Healthy volunteers
Hospital Universitario 12 de Octubre · Sites in Spain
Ages 0 days–30 days
Leiden University Medical Center · Sites in Spain, Austria, Belgium and 16 more countries
Ages up to 32 wk
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain
Ages 18+ · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 12 · Phase 4 6
First in 2003; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 162 is above the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 121 across the 56 interventional studies, 160 across the 17 observational. Of the 43 that completed or were terminated, 8 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 73 have an industry lead sponsor. The 10 most frequent:
University of Barcelona is the lead sponsor of 100 studies on the registry; 30 are open to participants now.
University of Barcelona has 1 study filed under Premature Birth — fewer than ten, so there is no comparison to draw.
2 of the studies in Premature Birth with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06224816Hospital Universitario 12 de OctubreClinical Trial for the Evaluation of Customized 3D Printed NIV Nasal Masks in Premature Infants | 2026-12 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 73 studies in Premature Birth with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the effectiveness of a breastfeeding support and promotion program to increase exclusive breastfeeding rates in the preterm group. The intervention is performed by an Advanced Practice Nurse and International Board Certified Breastfeeding Consultant (IBCLC), with high expertise in breastfeeding problems. It is a combination of face-to-face, home care and telephone attention to improve the adherence to breastfeeding. The intervention lasts 6 months.
Will be included moderately premature infants to the Neonatal Unit of the Hospital Clínic who achieve with the inclusion criteria of the study. The sample calculation includes 162 subjects to increase breastfeeding rates to 70% at discharge, 50% at 3 months and 40% at 6 months of the babies. Mothers who wish to exclusively breastfeed up to 6 months and sign the informed consent, will be randomized into the experimental group or control group. The control group will receive usual care and the experimental group will receive 1 pre-discharge face-to-face session, 8 home care sessions up to 4 months and 3 telephone follow-up sessions up to 6 months of baby.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The Control Group receives the usual intervention from the health center, that consists in breastfeeding support in the NICU 1 time/week until hospital discharge.
The Experimental Group receives the PAP-LM programme.
Other: Programme to Support Breastfeeding
The intervention consists of active support for breastfeeding by a lactation expert and IBCLC until the premature baby is 6 months old. The intervention includes: 1 face-to-face pre-discharge session, 8 home sessions up to 4 months and 3 telephone sessions up to 6 months.
BREASTFEEDING RATES
Exclusive Breastfeeding or Parcial Breastfeeding
Time frame: 15 days postpartum, at 3 months and at 6 months postpartum
PREMATURE GROWTH
Kilograms, percentiles and Z-scores of weight
Time frame: 15 days postpartum, at 3 and 6 months postpartum
PREMATURE HEIGHT
Meters, percentiles and Z-scores of height
Time frame: 15 days postpartum, at 3 and 6 months postpartum
PREMATURE CRANIAL PERIMETER
Meters, percentiles and Z-scores of head circumference
Time frame: 15 days postpartum, at 3 and 6 months postpartum
PUNTUATION IN DEVELOPMENT WITH ASQ-3
Total puntuation in Ages And Stages Questionnarie of Development (ASQ-3)
Time frame: At 6 months postpartum
MOTHER EFFICACY WITH BREASTFEEDING (USING BSES)
The Breastfeeding Self-Efficacy Scale (BSES) is a tool that helps assess how confident a mother feels about her ability to breastfeed. Based on the idea that believing in yourself impacts success, the scale uses 14 questions to measure a mother's sense of capability in different breastfeeding tasks. The higher her score, the more confident she feels. This scale is commonly used by healthcare providers and researchers to better understand where mothers might need extra support, as confidence plays a key role in how long and how successfully they continue breastfeeding.
Time frame: 15 days postpartum and at 6 months postpartum
Plan to share: No — The information will be confidential. Participation in the study will be voluntary and optional. Participants may leave the study at any time. No data or results will be transferred to patients.
Ran from Oct 2021 to primary completion in Feb 2024, 28 months.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 28 months is above that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.